Skip to main navigation Skip to search Skip to main content

An Expanded Access Program for Efgartigimod Treatment in Patients With Generalized Myasthenia Gravis

Grants and Contracts Details

StatusFinished
Effective start/end date11/19/2110/20/22

Funding

  • Argenx: $14,445.00